< Back to previous page
Researcher
Patrick Chaltin
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Intellectual Property (Administrative office)
Member
From16 Mar 2006 → 10 Apr 2017 - Department of Microbiology, Immunology and Transplantation (Department)
Member
From15 May 2002 → 31 Oct 2002 - Medicinal Chemistry (Rega Institute) (Division)
Member
From1 Oct 1999 → 14 May 2002
Projects
11 - 16 of 16
- Targeting the chromatin for innovative cancer therapy.From1 Nov 2014 → 31 Oct 2018Funding: SBO (Strategic basic research)
- Nuclear-cytoplasmic transport as novel therapeutic target.From1 Oct 2014 → 30 Sep 2018Funding: IOF - Industrial Research Fund
- Development of novel selective ghrelin O-acyltransferase inhibitors for the treatment of obesity and obesity-related type 2 diabetesFrom1 Apr 2014 → 31 Mar 2015Funding: IOF - Industrial Research Fund
- Validation of small molecule inhibitors of MALT1 protease for the treatment of auto-immune disorders and NF-κB-addicted lymphomas.From1 Oct 2013 → 30 Sep 2014Funding: IOF - Industrial Research Fund
- Evaluation of the (in vivo) efficacy of a novel class of broad-spectrum fungicidal compounds.From1 Jun 2009 → 31 May 2010Funding: IOF - Industrial Research Fund
- CD3 - the Centre for Drug Design and Discovery – discovering new drugs based on innovative researchFrom1 Oct 2006 → TodayFunding: IOF - Industrial Research Fund, IOF - mandates
Publications
1 - 10 of 44
- A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models.(2023)
Authors: Hanne Hillen, Weronika Kowalczyk, Patrick Chaltin, Georg Halder
Pages: OF1 - OF11 - Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model(2022)
Authors: Tom Van Loy, Steven De Jonghe, Wouter Dheedene, Patrick Chaltin, Aernout Luttun, Dominique Schols
- Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice(2021)
Authors: Patrick Chaltin
- Combining Cell Envelope Stress Reporter Assays in a Screening Approach to Identify BAM Complex Inhibitors(2021)
Authors: Patrick Chaltin
Pages: 2250 - 2263 - Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development(2021)
Authors: Patrick Chaltin
- Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development(2021)
Authors: Patrick Chaltin
- Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery(2020)
Authors: Rana Abdelnabi, Kim Donckers, Pieter Leyssen, Patrick Chaltin, Johan Neyts, Leen Delang
- Functional expression and pharmacological modulation of TRPM3 in human sensory neurons(2020)
Authors: Laura Vangeel, Katrien De Clercq, Patrick Chaltin, Catherine Verfaillie, Joris Vriens, Thomas Voets
Pages: 2683 - 2695 - Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors(2018)
Authors: Suzanne Kaptein, Kai Dallmeier, Patrick Chaltin, Johan Neyts
Pages: 8390 - 8401 - Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer's disease(2018)
Authors: Wim Dehaen, Joris Winderickx, Patrick Chaltin
Patents
1 - 10 of 10
- Aryl derivatives for treating trpm3 mediated disorders (Inventor)
- Heterocycle derivatives for treating trpm3 mediated disorders (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders (Inventor)
- Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- Thieno[2,3-b]pyridine derivatives as viral replication inhibitors (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- N-((1h-indol-3-yl)-alkyl)-4-benzyl)benzamide and n-((1h-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders (Inventor)
- N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders (Inventor)